{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:23:18Z","timestamp":1768976598637,"version":"3.49.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Relentless placoid chorioretinitis is a rare condition, and although it may require long-term immunosuppressive therapy, there are no standardized treatment guidelines. Within this study, we discuss outcomes of the largest group of patients from a single institution with a diagnosis of relentless placoid chorioretinitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a retrospective cohort study of patients diagnosed with relentless placoid chorioretinitis treated at the Associated Retinal Consultants in Royal Oak, Michigan from January 2015 to January 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of eight patients (11 eyes) were included. Initial treatments included oral prednisone (10 of 11 eyes) and topical steroids (5 of 11 eyes). Four patients were treated with methotrexate as their initial immunomodulatory therapy agent and achieved disease quiescence. One patient (2 eyes) was treated with cyclosporine followed by mycophenolate and successfully tapered off all therapy after remaining quiescent for more than 10 years. All patients were able to achieve control of disease activity with no active lesions on final follow-up. Visual acuity either improved or remained stable in all 11 eyes with presenting and final mean logMAR visual acuities of 0.61 (20\/80, Snellen) and 0.10 (20\/25, Snellen), respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013) [a mean of 3.4 lines of improvement]. The four patients treated with methotrexate had presenting and final mean logMAR visual acuities of 1.13 (20\/320, Snellen) and 0.27 (20\/40, Snellen), respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.047) [a mean of six lines of improvement].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>To our knowledge, this is the largest cohort of relentless placoid chorioretinitis patients in a single study. Care for these patients involves multimodal imaging as well as multidisciplinary care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004674","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:01:10Z","timestamp":1757966470000},"page":"249-254","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["MULTIMODAL IMAGING AND LONG-TERM TREATMENT OUTCOMES OF RELENTLESS PLACOID CHORIORETINITIS"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9000","authenticated-orcid":false,"given":"Viren K.","family":"Govindaraju","sequence":"first","affiliation":[{"name":"Associated Retinal Consultants, Royal Oak, Michigan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Moinuddin","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, Royal Oak, Michigan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Skender","sequence":"additional","affiliation":[{"name":"Beaumont Eye Institute, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"Faia","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, Royal Oak, Michigan; and"},{"name":"Beaumont Eye Institute, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260120","doi-asserted-by":"crossref","first-page":"885230","DOI":"10.3389\/fped.2023.885230","article-title":"Relentless placoid chorioretinitis: a review of four cases in pediatric and young adult patients with a discussion of therapeutic strategies","volume":"11","author":"Zaheer","year":"2023","journal-title":"Front Pediatr"},{"key":"R2-20260120","first-page":"931","article-title":"Relentless placoid chorioretinitis: a new entity or an unusual variant of serpiginous chorioretinitis?","volume":"118","author":"Jones","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R3-20260120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/archophthalmol.2009.12","article-title":"Relentless placoid chorioretinitis associated with central nervous system lesions treated with mycophenolate mofetil","volume":"127","author":"Yeh","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R4-20260120","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.ajo.2022.08.018","article-title":"Subretinal exudation and fibrosis in relentless placoid chorioretinitis","volume":"243","author":"Wu","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R5-20260120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ajoc.2019.03.005","article-title":"Cyclosporine and prednisolone combination therapy as a potential therapeutic strategy for relentless placoid chorioretinitis","volume":"14","author":"Uraki","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R6-20260120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09273940903402637","article-title":"Clinical profile, treatment, and visual outcome of ampiginous choroiditis","volume":"18","author":"Jyotirmay","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R7-20260120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1442-9071.2008.01773.x","article-title":"Optical coherence tomography in relentless placoid chorioretinitis","volume":"36","author":"Amer","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"key":"R8-20260120","doi-asserted-by":"crossref","first-page":"13115","DOI":"10.12998\/wjcc.v10.i35.13115","article-title":"Systemic combined with intravitreal methotrexate for relentless placoid chorioretinitis: a case report","volume":"10","author":"Luo","year":"2022","journal-title":"World J Clin Cases"},{"key":"R9-20260120","first-page":"419","article-title":"Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis","volume":"7","author":"Srivastava","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"R10-20260120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/mr\/roac156","article-title":"Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"R11-20260120","first-page":"1156","article-title":"A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis","volume":"29","author":"Choi","year":"2002","journal-title":"J Rheumatol"},{"key":"R12-20260120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000500077","article-title":"Relentless placoid chorioretinitis: a case series of successful tapering of systemic immunosuppressants achieved with adalimumab","volume":"10","author":"Asano","year":"2019","journal-title":"Case Rep Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:00:29Z","timestamp":1768928429000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004674","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}